• Bromocriptine mesylate (2-bromo-α-ergocryptine) has proved to be useful in reducing the size of prolactin-secreting pituitary adenomas, but little evidence has accumulated about its effectiveness within the first two weeks of therapy. The patient described herein showed a rapid reduction in the size of the suprasellar extension of a prolactinoma and a dramatic improvement of the primary visual field abnormalities within two weeks of starting bromocriptine therapy. This experience exemplifies the potential use of the drug in acutely decompressing the anterior intracranial visual pathways.
Grimson BS, Bowman ZL. Rapid Decompression of Anterior Intracranial Visual Pathways With Bromocriptine. Arch Ophthalmol. 1983;101(4):604–606. doi:10.1001/archopht.1983.01040010604015
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.